Drug reference
Community-acquired pneumonia ▶BY INTRAVENOUS INFUSION ▶Adult: 600 mg every 12 hours for 5–7 days Complicated skin infections | Complicated soft-tissue infections ▶BY INTRAVENOUS INFUSION ▶Adult: 600 mg every 12 hours for 5–14 days, for high dose regimen consult product literature
PDF page 581
Seizure disorders
PDF page 581
Scottish Medicines Consortium (SMC) decisions Infection The Scottish Medicines Consortium, has advised (Dec 2012) that ceftaroline fosamil (Zinforo ®) is accepted for restricted use within NHS Scotland when meticillin– resistant S. aureus is suspected in complicated skin and soft-tissue infection and vancomycin cannot be used.
PDF page 582
→Appendix 1: cephalosporins
PDF page 581
▶Uncommon Anaemia. antibiotic associated colitis. hypersensitivity
PDF page 581
Manufacturer advises avoid unless essential—limited information; animal studies do not indicate toxicity.
PDF page 581
Manufacturer advises avoid—no information available.
PDF page 581
Dose adjustments Manufacturer advises reduce dose if creatinine clearance less than 51 mL/minute—consult product literature.
PDF page 581
For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Dilute reconstituted solution to 50, 100, or 250 mL with infusion fluid; give over 5 to 60 minutes. Consult product literature for administration of high-dose regimen.
PDF page 582
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Zinforo (Pfizer Ltd) Ceftaroline fosamil (as Ceftaroline fosamil acetic acid solvate monohydrate) 600 mg Zinforo 600mg powder for concentrate for solution for infusion vials | 10 vial P £375.00 (Hospital only) eiiii F 550
PDF page 582
600 mg every 12 hours for 5–7 days
First-line fragment. Read the complete Indications and Dose section above.
PDF page 581
600 mg every 12 hours for 5–14 days, for high
First-line fragment. Read the complete Indications and Dose section above.
PDF page 581
